Jude Ediae, MD
Cardiovascular Disease · Lewes, DENPI 1619137569
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,519 of the $13,029 with a category attached, or 88.4%. 32 manufacturers reported payments, led by Medtronic at 42.0% of the total. Reporting peaked in 2019 at $4,073 and has fallen 64.7% since, to $1,437 in 2025.
Across 327 payments — averaging $39.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Boston Scientific$1K
- Pfizer$699
- AstraZeneca$616
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$609
- E.r. Squibb & Sons, L.L.C.$579
- plus $4K from 26 others
What the payments were for
- Travel & lodging$1,49111%
- Food & beverage$11,51988%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 92 | $5,466 |
| Boston Scientific | 30 | $1,261 |
| Pfizer | 23 | $699 |
| AstraZeneca | 33 | $616 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 32 | $609 |
| E.r. Squibb & Sons, L.L.C. | 10 | $579 |
| Cardiovascular Systems Inc. | 10 | $574 |
| Amgen | 21 | $455 |
| Edwards Lifesciences | 3 | $403 |
| Boehringer Ingelheim | 5 | $311 |
| Abiomed | 5 | $305 |
| Novartis | 11 | $294 |
| Johnson & Johnson | 14 | $215 |
| Corindus Inc. | 1 | $149 |
| Esperion Therapeutics, Inc. | 7 | $123 |
| Alnylam Pharmaceuticals Inc. | 3 | $114 |
| Abbott | 3 | $113 |
| Shockwave Medical, Inc | 1 | $96 |
| Sanofi-aventis U.S. LLC | 1 | $91 |
| Bardy Diagnostics, Inc. | 1 | $88 |
| Amarin Pharma, Inc. | 5 | $85 |
| Stryker | 2 | $78 |
| Baxter Healthcare | 3 | $66 |
| Lexicon Pharmaceuticals, Inc. | 1 | $61 |
| Lundbeck LLC | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Philips North America LLC | 1 | $25 |
| Bridgebio Pharma, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Preventice Services, LLC | 1 | $14 |
| Teleflex LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$1,491
- Micra$392
- VYNDAQEL$365
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$288
- GENERAL - STENTS$240
- Impella$227
- GENERAL ULTRASOUND$225
- RESOLUTE ONYX$222
- Coronary Orbital Atherectomy System$218
- CorPath GRX$149
- LINQ II$147
- JARDIANCE$125
- Azure$121
- ELIQUIS$120
- PRADAXA$120
- GENERAL VASCULAR INTERVENTION$119
- CAMZYOS$119
- SYNERGY$115
- Edwards SAPIEN 3 Transcatheter Heart Valve$115
- Claria MRI$112
How this compares
$13,029 in reported general payments places this provider in the 80th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 314 | $415,718 |
| EntrestoSacubitril/Valsartan | 45 | $80,539 |
| XareltoRivaroxaban | 58 | $75,571 |
| JardianceEmpagliflozin | 38 | $49,770 |
| Repatha SureclickEvolocumab | 32 | $34,562 |
| Praluent PenAlirocumab | 30 | $30,828 |
| BrilintaTicagrelor | 27 | $27,097 |
| Rosuvastatin Calcium | 770 | $15,834 |
| FarxigaDapagliflozin Propanediol | 11 | $15,289 |
| Metoprolol Succinate | 574 | $9,829 |
| Ezetimibe | 219 | $5,771 |
| Bisoprolol Fumarate | 178 | $5,759 |
| Ranolazine ErRanolazine | 27 | $5,038 |
| Atorvastatin Calcium | 353 | $4,509 |
| Losartan Potassium | 337 | $4,256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $699 | $415,718314 claims |
| NovartisEntresto | $294 | $80,53945 claims |
| Johnson & JohnsonXarelto | $215 | $75,57158 claims |
| Boehringer IngelheimJardiance | $311 | $49,77038 claims |
| AstraZenecaBrilinta, Farxiga | $616 | $42,38538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Lewes
- Rajinder PrasadLewes$72K
- Ehtasham QureshiLewes$52K
- Mouhanad FreihLewes$20K
- Ramon RosaLewes$12K
- Kenneth SunnergrenLewes$11K
- Gene MyersLewes$6K
- Praveen GeorgeLewes$5K
- Vinay HosmaneWilmington$256K
- Wasif QureshiBear$122K
- Edward GoldenbergNewark$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.